Literature DB >> 17644745

Lenalidomide therapy in a patient with POEMS syndrome.

Angela Dispenzieri, Christopher J Klein, Michelle L Mauermann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17644745     DOI： 10.1182/blood-2007-03-082354

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  23 in total

1.  POEMS syndrome with severe neurological damage clinically recovered with lenalidomide.

Authors:  José F Tomás; Pilar Giraldo; Ramón Lecumberri; Sara Nistal
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 2.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

3.  High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation.

Authors:  Gordon Cook; Simona Iacobelli; Anja van Biezen; Dimitris Ziagkos; Veronique LeBlond; Julie Abraham; Grant McQuaker; Stefan Schoenland; Alessandro Rambaldi; Kazimierz Halaburda; Maria Rovira; Simona Sica; Jenny Byrne; Ramon Garcia Sanz; Arnon Nagler; Niels W C J van de Donk; Marjatta Sinisalo; Mark Cook; Nicolaus Kröger; Theo De Witte; Curly Morris; Laurant Garderet
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

4.  Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome.

Authors:  Benjamin F Chu; Arwa Shana'ah; Craig C Hofmeister; Don M Benson; Megan Sell; Jill Tucker; Flavia Pichiorri; Yvonne A Efebera
Journal:  Eur J Case Rep Intern Med       Date:  2014

Review 5.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

6.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.

Authors:  Xinping Zhou; Juying Wei; Yinjun Lou; Gaixiang Xu; Min Yang; Hui Liu; Liping Mao; Hongyan Tong; Jie Jin
Journal:  Front Med       Date:  2017-04-03       Impact factor: 4.592

7.  Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome.

Authors:  J Li; M-H Duan; C Wang; X-F Huang; W Zhang; X-X Cao; T-N Zhu; J-L Zhuang; B Han; H Cai; H-C Cai; D-B Zhou
Journal:  Leukemia       Date:  2017-01-19       Impact factor: 11.528

Review 8.  Development of POEMS syndrome after an initial manifestation of solitary plasmacytoma.

Authors:  Motohiro Shindo; Kazuya Sato; Masayo Yamamoto; Yasumichi Toki; Mayumi Hatayama; Satoshi Ito; Kazuhiko Ichiki; Naoka Okamura; Takaaki Hosoki; Katsuya Ikuta; Junki Inamura; Shinji Watanabe; Yoshihiro Torimoto; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2011-05-07       Impact factor: 2.490

Review 9.  How I treat POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

Review 10.  Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.

Authors:  Satoshi Kuwabara; Angela Dispenzieri; Kimiyoshi Arimura; Sonoko Misawa; Chiaki Nakaseko
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.